Hans-Joachim Schmoll

8PUBLICATIONS
45CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsCardiology (incl. cardiovascular diseases)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 04, 2024
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.

Benoist Chibaudel, Morteza Raeisi, Romain Cohen

|Jul 17, 2024
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer.

Marinde J G Bond, Maarten van Smeden, Koen Degeling

|Mar 28, 2024
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.

Claire Gallois, Qian Shi, Levi D Pederson

|Dec 05, 2021
Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.

Richard M Goldberg, Richard Adams, Marc Buyse

|Oct 19, 2020
The future of colorectal cancer research: an interview with Hans Schmoll.

Hans-Joachim Schmoll

|Oct 01, 2020
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.

Hans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem

Pageof 2

Frequent Collaborators

3 joint publications

Qian Shi

3 joint publications

Thierry André

3 joint publications

Richard M Goldberg

3 joint publications

Aimery de Gramont